Diversified Consumer Services
Company Overview of Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai is a center for medical and scientific training. Icahn School of Medicine at Mount Sinai operates as a subsidiary of The Mount Sinai Hospital.
One Gustave L. Levy Place
New York, NY 10029-6574
Founded in 1968
Key Executives for Icahn School of Medicine at Mount Sinai
Vice President of Technology and Business Development
Compensation as of Fiscal Year 2015.
Icahn School of Medicine at Mount Sinai Key Developments
Icahn School of Medicine at Mount Sinai Presents at 14th Annual BIO Investor Forum, Oct-20-2015 09:00 AM
Sep 21 15
Icahn School of Medicine at Mount Sinai Presents at 14th Annual BIO Investor Forum, Oct-20-2015 09:00 AM. Venue: Parc 55 Hotel, San Francisco, California, United States. Speakers: Pamela Sklar, Chief, Division of Psychiatric Genomics.
Mount Sinai School Of Medicine Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 09:00 AM
Aug 12 14
Mount Sinai School Of Medicine Presents at Citi's 9th Annual Biotech Conference, Sep-04-2014 09:00 AM. Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States. Speakers: Patrizia Cassaccia, M.D., Ph.D., Professor of Neuroscience & Genetics & Genomics.
DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn's Disease
Feb 18 14
DBV Technologies and the Icahn School of Medicine at Mount Sinai announced that they entered into a research collaboration agreement to investigate the efficacy and mechanism of epicutaneous tolerance utilizing Viaskin(R) for the treatment of Crohn's disease. Crohn's disease is a chronic condition for which there is currently no satisfactory cure able to increase the quality of life for people who have Crohn's disease. DBV has already proven, in several pre-clinical studies that repeated epicutaneous immunotherapy (EPIT(TM)) leads to increase natural and induced immune regulatory cells. Preliminary studies already showed that these immune regulatory cells play an essential role in by protecting the gut from inflammation. DBV partn ered with the Mount Sinai team, which has world-class expertise in cellular mechanisms involved in Crohn's disease, having already demonstrated that administration of Tregs to patients with severe Crohn's disease was well tolerated and efficacious. DBV has established that Induction of immune regulatory cells can be achieved by epicutaneous exposure. The combination of DBV's technology with Mount Sinai's expertise could lead to a first-in-class approach to induce tolerance and decrease gut inflammation. The Collaboration will explore a novel approach to treat Crohn's disease based on epicutaneous delivery with Viaskin(R) to induce regulatory cells (Treg). Pre-clinical studies will aim at: Evaluating the ability of epicutaneous tolerance induction with Viaskin(R) to treat inflammatory colitis; Demonstrating the functional ability of antigen-specific Tregs induced by epicutaneous exposure with Viaskin(R) in suppressing inflammatory responses in the gut; and Acquiring a better knowledge of cellular mechanisms involved. These activities and studies are expected to last at least 12 months.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries